熱點掃描 | 特斯拉概念股走高，雅迪控股漲超7%
uSMART盈立智投3月30日消息，截止發稿，港股三大指數齊漲，恆生指數上漲1.16%，報22178.83點，成交額735.82億；國企指數上漲0.99%，報7587.24點，成交額304.84億；紅籌指數上漲0.92%，報3981.02點，成交額31.2億。
汽車股拉昇，蔚來、小鵬、吉利汽車漲超5%，長城漲超4%，五菱汽車、比亞迪股份漲超1%；
特斯拉概念股走高，雅迪控股漲超7%，耐世特、福耀玻璃、力勁科技漲超5%，贛鋒鋰業漲超3%；
綠電概念大漲，華能國際電力、中廣核新能源、龍源電力漲超5%，金風科技、中國電力、大唐新能源漲超4%
陽光紙業漲超6%領漲紙業股，玖龍紙業、理文造紙漲超2%；
煤炭股普跌，兗礦能源跌超3%，伊泰煤炭、中國神華、中煤能源跌超2%；
熱門股
信達生物漲超5%，報30.3港元，信達生物公告，2021年度，公司總收入爲人民幣42.61億元，同比增加74.1%。截至2021年12月31日止年度的產品收入達人民幣40.01億元，同比增長69%。主導產品達伯舒（信迪利單抗注射液）作爲抗程序性細胞死亡蛋白1（PD-1）市場的領先品牌，在銷售收入及銷量上均保持強勁增長；
海螺環保上市首日飆升近29%，報12.86港元，據悉，公司分拆自海螺創業，分拆及上市完成後，該公司將繼續主要從事現有的工業固危廢處置業務；而海螺創業集團將繼續主要從事垃圾發電項目、新型建築材料及港口物流業務。按收入計算，公司於2020年爲中國的最大水泥窯協同處置服務供應商，同時也爲中國使用水泥窯協同處置技術處置工業固危廢的最大服務供應商，按營運中的處置能力計算佔總市場份額的約21.7%，按處置量計算佔總市場份額約31.1%；
康寧傑瑞製藥漲8.72%，報8.6港元，公司2021年實現收入1.46億元，毛利達1.43億元。期內，公司的研發開支同比大增45.35%至4.81億元。據悉，公司於2021年末開始商業化KN035(恩沃利單抗)，並於2021年8月與津曼特生物科技訂立許可協議，在中國內地開發及商業化用於治療乳腺癌及GC的KN026。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.
